In 1380 biopsy-proven NAFLD patients, we recently showed that the co-presence of PNPLA3 I148M, MBOAT7 rs641738, and TM6SF2 E167K genetic variations was associated with advanced liver disease and HCC development independently of higher transaminases levels, cholesterol, and BMI, thus corroborating their synergistic role in progressive NAFLD [6]. This evidence concerns the gene TM6SF2 and hepatocellular carcinoma.